E2NO34 Stock Overview
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Enovis Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$66.47 |
| 52 Week High | US$80.96 |
| 52 Week Low | US$63.76 |
| Beta | 2.06 |
| 1 Month Change | 0% |
| 3 Month Change | 4.25% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -15.94% |
Recent News & Updates
Recent updates
Shareholder Returns
| E2NO34 | BR Medical Equipment | BR Market | |
|---|---|---|---|
| 7D | 0% | 0.4% | 0.9% |
| 1Y | n/a | -1.8% | 15.2% |
Return vs Industry: Insufficient data to determine how E2NO34 performed against the BR Medical Equipment industry.
Return vs Market: Insufficient data to determine how E2NO34 performed against the BR Market.
Price Volatility
| E2NO34 volatility | |
|---|---|
| E2NO34 Average Weekly Movement | n/a |
| Medical Equipment Industry Average Movement | 6.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 9.0% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: E2NO34 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine E2NO34's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1995 | 6,550 | Matt Trerotola | www.enovis.com |
Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.
Enovis Corporation Fundamentals Summary
| E2NO34 fundamental statistics | |
|---|---|
| Market cap | R$16.22b |
| Earnings (TTM) | -R$271.73m |
| Revenue (TTM) | R$8.53b |
1.9x
P/S Ratio-59.7x
P/E RatioIs E2NO34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| E2NO34 income statement (TTM) | |
|---|---|
| Revenue | US$1.71b |
| Cost of Revenue | US$713.67m |
| Gross Profit | US$993.53m |
| Other Expenses | US$1.05b |
| Earnings | -US$54.37m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.00 |
| Gross Margin | 58.20% |
| Net Profit Margin | -3.18% |
| Debt/Equity Ratio | 13.6% |
How did E2NO34 perform over the long term?
See historical performance and comparison